|
1
|
Kovacs G, Dumitrescu D, Barner A, Greiner
S, Grünig E, Hager A, Köhler T, Kozlik-Feldmann R, Kruck I, Lammers
AE, Mereles D, et al: Definition, clinical classification and
initial diagnosis of pulmonary hypertension: Updated
recommendations from the cologne consensus conference 2018. Int J
Cardiol. 272S:11–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lan NSH, Massam BD, Kulkarni SS and Lang
CC: Pulmonary arterial hypertension: Pathophysiology and treatment.
Diseases. 6:382018. View Article : Google Scholar
|
|
3
|
Guiot J, Parzibut G, Weber T, Davin L,
Dulgheru R, Lancellotti P, Louis R and Vachiery JL: Pulmonary
arterial hypertension. Rev Med Liege. 74:139–45. 2019.(In French).
PubMed/NCBI
|
|
4
|
Thenappan T, Ormiston ML, Ryan JJ and
Archer SL: Pulmonary arterial hypertension: Pathogenesis and
clinical management. BMJ. 360:j54922018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Javadian M, Gharibi T, Shekari N,
Abdollahpour-Alitappeh M, Mohammadi A, Hossieni A, Mohammadi H and
Kazemi T: The role of microRNAs regulating the expression of matrix
metalloproteinases (MMPs) in breast cancer development,
progression, and metastasis. J Cell Physiol. 234:5399–5412. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Rooij E: The art of microRNA research.
Circ Res. 108:219–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dawson K, Wakili R, Ordog B, Clauss S,
Chen Y, Iwasaki Y, Voigt N, Qi XY, Sinner MF, Dobrev D, et al:
MicroRNA29: A mechanistic contributor and potential biomarker in
atrial fibrillation. Circulation. 127:1466–1475, 1475e1-28. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eitel I, Adams V, Dieterich P, Fuernau G,
de Waha S, Desch S, Schuler G and Thiele H: Relation of circulating
MicroRNA-133a concentrations with myocardial damage and clinical
prognosis in ST-elevation myocardial infarction. Am Heart J.
164:706–714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng L, Blanco FJ, Stevens H, Lu R,
Caudrillier A, McBride M, McClure JD, Grant J, Thomas M, Frid M, et
al: MicroRNA-143 activation regulates smooth muscle and endothelial
cell crosstalk in pulmonary arterial hypertension. Circ Res.
117:870–883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Caruso P, Dunmore BJ, Schlosser K, Schoors
S, Dos Santos C, Perez-Iratxeta C, Lavoie JR, Zhang H, Long L,
Flockton AR, et al: Identification of MicroRNA-124 as a major
regulator of enhanced endothelial cell glycolysis in pulmonary
arterial hypertension via PTBP1 (Polypyrimidine Tract Binding
Protein) and pyruvate kinase M2. Circulation. 136:2451–2467. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rothman AM, Arnold ND, Pickworth JA,
Iremonger J, Ciuclan L, Allen RM, Guth-Gundel S, Southwood M,
Morrell NW, Thomas M, et al: MicroRNA-140-5p and SMURF1 regulate
pulmonary arterial hypertension. J Clin Invest. 126:2495–2508.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HW and Park SH: Elevated microRNA-135a
is associated with pulmonary arterial hypertension in experimental
mouse model. Oncotarget. 8:35609–35618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karakikes I, Chaanine AH, Kang S, Mukete
BN, Jeong D, Zhang S, Hajjar RJ and Lebeche D: Therapeutic
cardiac-targeted delivery of miR-1 reverses pressure
overload-induced cardiac hypertrophy and attenuates pathological
remodeling. J Am Heart Assoc. 2:e0000782013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin H, Zhao L, Zhang S, Zhang Y and Lei S:
MicroRNA1 suppresses cardiac hypertrophy by targeting nuclear
factor of activated T cells cytoplasmic 3. Mol Med Rep.
12:8282–8288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lapikova-Bryhinska T, Zhukovska A, Nagibin
V, Tumanovska L, Portnichenko G, Goncharov S, Portnychenko A and
Dosenko V: Altered biogenesis of microRNA-1 is associated with
cardiac dysfunction in aging of spontaneously hypertensive rats.
Mol Cell Biochem. 459:73–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mondejar-Parreno G, Callejo M, Barreira B,
Morales-Cano D, Esquivel-Ruiz S, Filice M, Moreno L, Cogolludo A
and Perez-Vizcaino F: miR-1 induces endothelial dysfunction in rat
pulmonary arteries. J Physiol Biochem. 75:519–529. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei L, Zhang Y, Qi X, Sun X, Li Y and Xu
Y: Ubiquitinproteasomes are the dominant mediators of the
regulatory effect of microRNA1 on cardiac remodeling after
myocardial infarction. Int J Mol Med. 44:1899–1907. 2019.PubMed/NCBI
|
|
20
|
Yang W, Wu Z, Yang K, Han Y, Chen Y, Zhao
W, Huang F, Jin Y and Jin W: BMI1 promotes cardiac fibrosis in
ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling
pathway. Am J Physiol Heart Circ Physiol. 316:H61–H69. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang CJ, Huang Y, Lu JD, Lin J, Ge ZR and
Huang H: Upregulated microRNA-132 rescues cardiac fibrosis and
restores cardiocyte proliferation in dilated cardiomyopathy through
the phosphatase and tensin homolog-mediated PI3K/Akt signal
transduction pathway. J Cell Biochem. Sep 14–2018.(Epub ahead of
print). doi: 10.1002/jcb.27081.
|
|
22
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. National Academies Press;
Washington, DC: 1996
|
|
23
|
Luo H, Liu B, Zhao L, He J, Li T, Zha L,
Li X, Qi Q, Liu Y and Yu Z: Galectin-3 mediates pulmonary vascular
remodeling in hypoxia-induced pulmonary arterial hypertension. J Am
Soc Hypertens. 11:673–683.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Pandey RN, York AJ, Mallela J,
Nichols WC, Hu YC, Molkentin JD, Wikenheiser-Brokamp KA and Hegde
RS: The EYA3 tyrosine phosphatase activity promotes pulmonary
vascular remodeling in pulmonary arterial hypertension. Nat Commun.
10:41432019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo Y, Teng X, Zhang L, Chen J, Liu Z,
Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-1alpha hypoxic
reprogramming drives vascular remodeling and pulmonary arterial
hypertension. Nat Commun. 10:35512019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao H, Ma TF, Lin J, Liu LL, Sun WJ, Guo
LX, Wang SQ, Otecko NO and Zhang YP: Identification of valid
reference genes for mRNA and microRNA normalisation in prostate
cancer cell lines. Sci Rep. 8:19492018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peltier HJ and Latham GJ: Normalization of
microRNA expression levels in quantitative RT-PCR assays:
Identification of suitable reference RNA targets in normal and
cancerous human solid tissues. Rna. 14:844–852. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inada K, Okoshi Y, Cho-Isoda Y, Ishiguro
S, Suzuki H, Oki A, Tamaki Y, Shimazui T, Saito H, Hori M, et al:
Endogenous reference RNAs for microRNA quantitation in
formalin-fixed, paraffin-embedded lymph node tissue. Sci Rep.
8:59182018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Z, Fang Z, Hu X and Zhou S: MicroRNAs
and mesenchymal stem cells: Hope for pulmonary hypertension. Rev
Bras Cir Cardiovasc. 30:380–385. 2015.PubMed/NCBI
|
|
31
|
Caruso P, MacLean MR, Khanin R, McClure J,
Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson
R, et al: Dynamic changes in lung microRNA profiles during the
development of pulmonary hypertension due to chronic hypoxia and
monocrotaline. Arterioscler Thromb Vasc Biol. 30:716–723. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou SS, Jin JP, Wang JQ, Zhang ZG,
Freedman JH, Zheng Y and Cai L: miRNAS in cardiovascular diseases:
Potential biomarkers, therapeutic targets and challenges. Acta
Pharmacol Sin. 39:1073–1084. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou G, Chen T and Raj JU: MicroRNAs in
pulmonary arterial hypertension. Am J Respir Cell Mol Biol.
52:139–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Courboulin A, Paulin R, Giguere NJ,
Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher
S, Côté J, et al: Role for miR-204 in human pulmonary arterial
hypertension. J Exp Med. 208:535–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tadic M, Cuspidi C, Bombelli M and Grassi
G: Right heart remodeling induced by arterial hypertension: Could
strain assessment be helpful? J Clin Hypertens (Greenwich).
20:400–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maron BA and Loscalzo J: Pulmonary
hypertension: Pathophysiology and signaling pathways. Handb Exp
Pharmacol. 218:31–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meloche J, Le Guen M, Potus F, Vinck J,
Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S,
Perros F, et al: miR-223 reverses experimental pulmonary arterial
hypertension. Am J Physiol Cell Physiol. 309:C363–C372. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McCann GP, Gan CT, Beek AM, Niessen HW,
Vonk Noordegraaf A and van Rossum AC: Extent of MRI delayed
enhancement of myocardial mass is related to right ventricular
dysfunction in pulmonary artery hypertension. AJR Am J Roentgenol.
188:349–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shehata ML, Lossnitzer D, Skrok J, Boyce
D, Lechtzin N, Mathai SC, Girgis RE, Osman N, Lima JA, Bluemke DA,
et al: Myocardial delayed enhancement in pulmonary hypertension:
Pulmonary hemodynamics, right ventricular function, and remodeling.
AJR Am J Roentgenol. 196:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hessel MH, Steendijk P, den Adel B,
Schutte CI and van der Laarse A: Characterization of right
ventricular function after monocrotaline-induced pulmonary
hypertension in the intact rat. Am J Physiol Heart Circ Physiol.
291:H2424–H2430. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Drake JI, Bogaard HJ, Mizuno S, Clifton B,
Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF and Natarajan R:
Molecular signature of a right heart failure program in chronic
severe pulmonary hypertension. Am J Respir Cell Mol Biol.
45:1239–1247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
MacLean J and Pasumarthi KB: Signaling
mechanisms regulating fibroblast activation, phenoconversion and
fibrosis in the heart. Indian J Biochem Biophys. 51:476–482.
2014.PubMed/NCBI
|
|
43
|
Zhang J, Fan G, Zhao H, Wang Z, Li F,
Zhang P, Zhang J, Wang X and Wang W: Targeted inhibition of focal
adhesion kinase attenuates cardiac fibrosis and preserves heart
function in adverse cardiac remodeling. Sci Rep. 7:431462017.
View Article : Google Scholar : PubMed/NCBI
|
